The leader in
RNA Cell Therapy

With multiple assets in clinical and preclinical development (see Pipeline), Cartesian is the leader in RNA Cell Therapy. Our mission is to unleash the reach and potential of cell therapy through RNA engineering.

RNA Cell Therapy is a new class of therapy that blends some of the best features from conventional nanoparticle-based RNA therapy with conventional DNA-engineered cell therapy.

In contrast to conventional nanoparticle-based RNA therapies, RNA Cell therapy may have minimal immunogenicity with repeat dosing. It can also be engineered with tissue-specific homing proteins.

Compared to conventional DNA-based cell therapies, RNA Cell Therapy has a predictable half-life and avoids the risk of genomic integration, attributes that are expected to make it safer. RNA Cell Therapy is also less expensive and enables true combination therapy without vector cargo limits.


Cartesian operates a wholly-owned, state-of-the-art GMP manufacturing facility in Gaithersburg, Maryland. By conducting all manufacturing in-house, we are able to optimize our processes rapidly and iteratively while directly assuring adherence to our strict quality standards. The resulting products are potent yet safer, cost-effective investigational cell therapies that can be administered with minimal training and post-infusion monitoring.


The RNA Armory® is our technology platform to engineer optimal RNA combinations into human cells. Currently we work with two types of cells, T-cells and Mesenchymal Stem Cells (MSCs). Our CAR T-cell programs harness the safety of RNA and autologous engineering to target autoimmune diseases and cancer – without toxic lymphodepletive chemotherapy. Our off-the-shelf MSC programs leverage these cells’ clinical safety record and excellent capacity for protein secretion to deliver synergistic combinations of therapies directly to the site of disease.

Scroll to Top